Three-Dimensional Cell Culture Models in Drug Discovery and Drug Repositioning
Overview
Authors
Affiliations
Drug development is a lengthy and costly process that proceeds through several stages from target identification to lead discovery and optimization, preclinical validation and clinical trials culminating in approval for clinical use. An important step in this process is high-throughput screening (HTS) of small compound libraries for lead identification. Currently, the majority of cell-based HTS is being carried out on cultured cells propagated in two-dimensions (2D) on plastic surfaces optimized for tissue culture. At the same time, compelling evidence suggests that cells cultured in these non-physiological conditions are not representative of cells residing in the complex microenvironment of a tissue. This discrepancy is thought to be a significant contributor to the high failure rate in drug discovery, where only a low percentage of drugs investigated ever make it through the gamut of testing and approval to the market. Thus, three-dimensional (3D) cell culture technologies that more closely resemble cell environments are now being pursued with intensity as they are expected to accommodate better precision in drug discovery. Here we will review common approaches to 3D culture, discuss the significance of 3D cultures in drug resistance and drug repositioning and address some of the challenges of applying 3D cell cultures to high-throughput drug discovery.
Revokatova D, Koteneva P, Kosheleva N, Shpichka A, Timashev P Sovrem Tekhnologii Med. 2025; 17(1):133-154.
PMID: 40071071 PMC: 11892564. DOI: 10.17691/stm2025.17.1.11.
Enhanced hepatitis E virus infection of polarised hepatocytes in vitro.
Brown H, Marlet J, Leon-Janampa N, Brand D, Fletcher N Sci Rep. 2025; 15(1):7598.
PMID: 40038434 PMC: 11880378. DOI: 10.1038/s41598-025-92164-9.
Paz M, Sette K, Dos Santos R, Barbosa E Vasconcelos A, Costa D, Amaral A Antioxidants (Basel). 2025; 14(2).
PMID: 40002328 PMC: 11851454. DOI: 10.3390/antiox14020141.
3D bioprinting for the production of a perfusable vascularized model of a cancer niche.
Maggiotto F, Bova L, Micheli S, Pozzer C, Fusco P, Sgarbossa P Front Bioeng Biotechnol. 2025; 13:1484738.
PMID: 39980862 PMC: 11841441. DOI: 10.3389/fbioe.2025.1484738.
Seymour S, Cadena I, Johnson M, Thakkar R, Jenne M, Adem I Cell Mol Bioeng. 2025; 18(1):71-82.
PMID: 39949489 PMC: 11813830. DOI: 10.1007/s12195-024-00841-y.